Six years of follow up. a prospective study on intravesical chemoprophylaxis with mitomycin-C and BCG alternating. Complete response rate and much lower tumor progression rate

The high rate of relapse and progresion of urotehal superficial tumors have not been resolved. Even though intravesical chemoprophylaxis as immunotherapy having used as therapies, still without reaching number of satisfactory prevention. It seems that the combination of some drugs obtain the most high rate of complete response to one year follow up (1), but after a year the results do not seem to be very positive. Data of a prospective and randomized study published in 1993 (2) proving the best rate of response in the arm using combination of drugs: alternating Mitomycin-C and BCG, that praised us to follow therapeutical post RTU in the superficial vesical tumors. A prospective follow up that lasted 6 years of all treated patients from January 1991 to December 1995, a total of 223 cases having the diagnosis Ca vesical transitional superficial pTa and pTl of any stage along with Cis and without Cis, all of them were submitted to this therapeutical, therefore, we obtained the following results: -4 intolerant patients were out of the study . eosinophilia cystitis (3). Complete response 205, rate of complete response 91%. Recidivation in 41 patients, 18.3%. Made stage progress or infiltrated stage on 16 patients, rate of progression of 7.1%. Establishing this norm of adjuvant chemoprophylaxis-immunotherapy post RTU with the combination of drugs, the results obtained were the best, with recidivation and progression with follow up of six years. At this moment, we think the best therapy is the combination of alternating drugs. 1. Superficial urinary bladder cancer. Results from the finnbladder studies and a review on instillations treatments. Ann. Chir. Gynaecol. Suppl. 206 (31-38), 1993. 2. Prospective and randomized study to a complete response, rate of recidivations and progression in the vesical superficial carcinoma treated with Mitomycin-C only vs. Mitomycin-C andBCG alternating. Arch. Esp. de Urol. 46,5(379-382). 1993 3. Eosinophilic cystitis and allergy to Mitomycin-C. Acta Urol. Belgica, 58 (65-66). 1990.